Published August 2018. VacZine Analytics' commercial intelligence on mRNA vaccines for infectious diseases is available in VAMV079 - mRNA Vaccines (Infectious Diseases), published March 2018.
A Surprising Entry into Influenza
There is growth in the global influenza vaccine market and the link between a better product and higher prices is now established - albeit mostly in the United States. Poor vaccine efficacy resurfaces the agenda for the ultimate product, but can Pfizer really leap-frog the efforts of the established players?
Pfizer Vaccines, a company not usually involved with influenza vaccines, announced an exciting investment in the German mRNA vaccine company BioNTech. The deal could be worth up to $425m ($120m upfront equity) and initiates a bold collaboration to develop new influenza vaccines.
Total potential value of the Pfizer-BioNTech collaboration, with $120m in upfront equity investment. The deal covers development of next-generation mRNA-based influenza vaccine candidates.
The mRNA Landscape in 2018
To date, commercial developers of mRNA vaccine technologies have attracted high interest from larger pharmaceutical companies and supranational grant authorities, but most deals had been directed to cancer, rare diseases, and metabolic indications. Examples included Eli Lilly with CureVac AG, Merck & Co with Moderna, and AstraZeneca with Moderna. For infectious diseases and "true" prophylactic mRNA vaccine candidates, activity had been comparatively limited: VacZine Analytics counted 21 mRNA clinical trials for infectious pathogens in February 2018 versus 67 for cancer, with most infectious disease trials investigating HIV.
The Pfizer-BioNTech deal followed a separate mRNA agreement announced in June 2018, when Sanofi Pasteur invested $45m upfront in Translate Bio for five undisclosed infectious disease pathogens - a multiyear collaboration to pursue 'next generation' vaccines.
"Pfizer's recent investment in BioNTech not only brings excitement to influenza vaccine R&D but more focus on the mRNA vaccine sector as a whole."
Why Influenza?
Pfizer's deal raises important strategic questions. There were quicker ways to enter the flu vaccine business, and involvement of other players in the mRNA space had not been productive to date. The collaboration must be primarily about access to the mRNA platform technology. For influenza specifically, the commercial rationale is well-established: it is a large, annually recurring market with well-understood seasonality, an established public payer infrastructure, and a clearly recognised need for improved vaccine efficacy - making it an ideal first indication for demonstrating mRNA platform utility in prophylactic vaccination.
Whether Pfizer can successfully navigate the complexities of an established, competitive vaccine market - dominated by Sanofi, GSK, and AstraZeneca - with a novel platform technology that had yet to deliver a licensed product remains the central question for the industry to watch.
This article is available in VacZine Analytics' Expert News archive as published in August 2018. For current intelligence on the mRNA vaccine pipeline, see VAMV079.